Halozyme withdraws $2.1 bln buyout offer for Evotec (updated)

Halozyme Therapeutics

22/11/2024 13:59

(Adds shares in paragraph 2, details in paragraph 3, background
in paragraph 4)
       Nov 22 (Reuters) - Halozyme Therapeutics  HALO.O  said
on Friday it had withdrawn its proposal to acquire Evotec SE
 EVTG.DE  for 2 billion euros  ($2.09 billion) as the German
drug developer was unwilling to engage in discussions.
    Shares of Halozyme rose 11% to $51, while U.S.-listed shares
of Evotec fell 18% to $4.4 in premarket trading.
        Halozyme's requests to meet and engage with Evotec's
Iris Löw-Friedrich, chairwoman of its supervisory board, were
not accepted, the company said.
        It had proposed to buy all shares of Evotec earlier this
month at 11 euros per share.
        
  
        
  


($1 = 0.9587 euros)

 (Reporting by Sriparna Roy in Bengaluru; Editing by Devika
Syamnath)
 ((Sriparna.Roy@thomsonreuters.com;))